文献速递糖尿病

1型糖尿病诊断后32年随访中HbA1c对严重视网膜病变和肾病发生的影响:VISS研究

Impact of HbA1c Followed 32 Years From Diagnosis of Type 1 Diabetes on Development of Severe Retinopathy and Nephropathy: The VISS Study.
PubMed 文献 · Diabetes Care · 2022-01-01

基于瑞典东南部1983至1987年诊断的447例1型糖尿病患者,随访至2019年,评估诊断起加权平均HbA1c对增殖性糖尿病视网膜病变(PDR)和肾病(大量白蛋白尿)的预测作用。32年后PDR患病率27%、大量白蛋白尿8%;PDR和肾病发生的最低加权平均HbA1c分别为7.3%(56 mmol/mol)和8.1%(65 mmol/mol)。作者建议在无严重低血糖且生活质量良好的前提下,HbA1c应低于7.0%(53 mmol/mol)并尽可能接近正常。

要点

  • 诊断起加权平均HbA1c是PDR和肾病的强生物标志物,32年后两者患病率仍上升。
  • 发生PDR和大量白蛋白尿的最低加权平均HbA1c分别为7.3%和8.1%。
  • 作者建议HbA1c低于7.0%并尽可能正常,前提是无严重低血糖且生活质量良好。

核心结论

  • 诊断起加权平均HbA1c是PDR和肾病的强生物标志物,32年后两者患病率仍增加。
  • 为避免1型糖尿病患者发生PDR和大量白蛋白尿,作者建议在无严重低血糖且生活质量良好时HbA1c低于7.0%(53 mmol/mol)并尽可能接近正常。

研究设计与样本

  • 基于人群的观察性研究,纳入1983至1987年瑞典东南部35岁前诊断的447例1型糖尿病患者,从诊断随访至2019年。
  • 通过整合所有HbA1c值曲线下面积计算长期加权平均HbA1c(wHbA1c),并按wHbA1c分为五个等级分析并发症。

主要发现

  • 32年后,9%无视网膜病变、64%为非PDR、27%为PDR;83%无微量白蛋白尿、9%有微量白蛋白尿、8%有大量白蛋白尿。
  • wHbA1c接近正常的患者未发生PDR或大量白蛋白尿。
  • 发生PDR和肾病(大量白蛋白尿)的最低wHbA1c值分别为7.3%(56 mmol/mol)和8.1%(65 mmol/mol)。
  • PDR和大量白蛋白尿患病率随wHbA1c升高而增加,在最高等级wHbA1c>9.5%(>80 mmol/mol)中分别为74%和44%。
  • 与20-24年随访相比,PDR患病率从14%增至27%,大量白蛋白尿从4%增至8%,且两者出现于更低的wHbA1c值。

关键数值与推荐

  • wHbA1c接近正常的患者未发生PDR或大量白蛋白尿。
  • 发生PDR的最低wHbA1c值为7.3%(56 mmol/mol),发生大量白蛋白尿的最低wHbA1c值为8.1%(65 mmol/mol)。
  • 最高等级wHbA1c>9.5%(>80 mmol/mol)中PDR患病率74%、大量白蛋白尿患病率44%。
  • 作者建议HbA1c<7.0%(53 mmol/mol)并尽可能正常,需在无严重低血糖且生活质量良好时达到。

临床怎么用

  • 作者建议对1型糖尿病患者,在无严重低血糖且生活质量良好时,HbA1c应低于7.0%(53 mmol/mol)并尽可能接近正常,以避免PDR和大量白蛋白尿。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate HbA1c followed from diagnosis, as a predictor of severe microvascular complications (i.e., proliferative diabetic retinopathy [PDR] and nephropathy [macroalbuminuria]). RESEARCH DESIGN AND METHODS: In a population-based observational study, 447 patients diagnosed with type 1 diabetes before 35 years of age from 1983 to 1987 in southeast Sweden were followed from diagnosis until 2019. Long-term weighted mean HbA1c (wHbA1c) was calculated by integrating the area under all HbA1c values. Complications were analyzed in relation to wHbA1c categorized into five levels. RESULTS: After 32 years, 9% had no retinopathy, 64% non-PDR, and 27% PDR, and 83% had no microalbuminuria, 9% microalbuminuria, and 8% macroalbuminuria. Patients with near-normal wHbA1c did not develop PDR or macroalbuminuria. The lowest wHbA1c values associated with development of PDR and nephropathy (macroalbuminuria) were 7.3% (56 mmol/mol) and 8.1% (65 mmol/mol), respectively. The prevalence of PDR and macroalbuminuria increased with increasing wHbA1c, being 74% and 44% in the highest category, wHbA1c >9.5% (>80 mmol/mol). In comparison with the follow-up done after 20-24 years' duration, the prevalence of PDR had increased from 14 to 27% and macroalbuminuria from 4 to 8%, and both appeared at lower wHbA1c values. CONCLUSIONS: wHbA1c followed from diagnosis is a very strong biomarker for PDR and nephropathy, the prevalence of both still increasing 32 years after diagnosis. To avoid PDR and macroalbuminuria in patients with type 1 diabetes, an HbA1c <7.0% (53 mmol/mol) and as normal as possible should be recommended when achievable without severe hypoglycemia and with good quality of life.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Arnqvist HJ, Westerlund MC, Fredrikson M, et al. Impact of HbA1c Followed 32 Years From Diagnosis of Type 1 Diabetes on Development of Severe Retinopathy and Nephropathy: The VISS Study. Diabetes Care. 2022. PMID: 36094113. doi:10.2337/dc22-0239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。